Michel Kranendonk

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7832874/publications.pdf

Version: 2024-02-01

430442 476904 39 930 18 29 citations g-index h-index papers 46 46 46 873 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	" <i>Commandeuring</i> à€•Xenobiotic Metabolism: Advances in Understanding Xenobiotic Metabolism. Chemical Research in Toxicology, 2022, 35, 1184-1201.	1.7	4
2	Electrochemical Activity of Cytochrome P450 1A2: The Relevance of O ₂ Control and the Natural Electron Donor. ChemElectroChem, 2021, 8, 500-507.	1.7	2
3	Electrochemical Activity of Cytochrome P450 1A2: The Relevance of O 2 Control and the Natural Electron Donor. ChemElectroChem, 2021, 8, 430-430.	1.7	O
4	The Central Role of Cytochrome P450 in Xenobiotic Metabolism—A Brief Review on a Fascinating Enzyme Family. Journal of Xenobiotics, 2021, 11, 94-114.	2.9	164
5	Advanced preclinical models for evaluation of drug-induced liver injury – consensus statement by the European Drug-Induced Liver Injury Network [PRO-EURO-DILI-NET]. Journal of Hepatology, 2021, 75, 935-959.	1.8	66
6	Interaction Modes of Microsomal Cytochrome P450s with Its Reductase and the Role of Substrate Binding. International Journal of Molecular Sciences, 2020, 21, 6669.	1.8	9
7	The Role of the FMN-Domain of Human Cytochrome P450 Oxidoreductase in Its Promiscuous Interactions With Structurally Diverse Redox Partners. Frontiers in Pharmacology, 2020, 11, 299.	1.6	22
8	A personally guided tour on some of our data with the Ames assay—A tribute to Professor Bruce Ames. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2019, 846, 503094.	0.9	3
9	Accurate Determination of Human CPR Conformational Equilibrium by smFRET Using Dual Orthogonal Noncanonical Amino Acid Labeling. ChemBioChem, 2019, 20, 659-666.	1.3	13
10	Probing the Role of the Hinge Segment of Cytochrome P450 Oxidoreductase in the Interaction with Cytochrome P450. International Journal of Molecular Sciences, 2018, 19, 3914.	1.8	16
11	Human cytochrome P450 expression in bacteria: Whole-cell high-throughput activity assay for CYP1A2, 2A6 and 3A4. Biochemical Pharmacology, 2018, 158, 134-140.	2.0	7
12	The Hinge Segment of Human NADPH-Cytochrome P450 Reductase in Conformational Switching: The Critical Role of Ionic Strength. Frontiers in Pharmacology, 2017, 8, 755.	1.6	21
13	Editorial: Role of Protein-Protein Interactions in Metabolism: Genetics, Structure, Function. Frontiers in Pharmacology, 2017, 8, 881.	1.6	5
14	Prototype Systems Containing Human Cytochrome P450 for High-Throughput Real-Time Detection of DNA Damage by Compounds That Form DNA-Reactive Metabolites. Chemical Research in Toxicology, 2016, 29, 747-756.	1.7	2
15	Instability of the Human Cytochrome P450 Reductase A287P Variant Is the Major Contributor to Its Antley-Bixler Syndrome-like Phenotype. Journal of Biological Chemistry, 2016, 291, 20487-20502.	1.6	26
16	Cytochrome P450 expression system for high-throughput real-time detection of genotoxicity: Application to the study of human CYP1A2 variants. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2016, 806, 24-33.	0.9	4
17	Human Sulfotransferase 1A1-Dependent Mutagenicity of 12-Hydroxy-nevirapine: The Missing Link?. Chemical Research in Toxicology, 2014, 27, 1967-1971.	1.7	9
18	Functional characterization of eight human CYP1A2 variants. Pharmacogenetics and Genomics, 2013, 23, 41-52.	0.7	25

#	Article	IF	CITATIONS
19	Altered Human CYP3A4 Activity Caused by Antley-Bixler Syndrome-Related Variants of NADPH-Cytochrome P450 Oxidoreductase Measured in a Robust In Vitro System. Drug Metabolism and Disposition, 2012, 40, 754-760.	1.7	27
20	Human Cytochrome P450 Oxidoreductase Deficiency Caused by the Y181D Mutation: Molecular Consequences and Rescue of Defect. Drug Metabolism and Disposition, 2010, 38, 332-340.	1.7	49
21	Functional characterization of eight human cytochrome P450 1A2 gene variants by recombinant protein expression. Pharmacogenomics Journal, 2010, 10, 478-488.	0.9	27
22	Alkylating Potential of Oxetanes. Chemical Research in Toxicology, 2010, 23, 1275-1281.	1.7	5
23	Simple and sensitive antimalarial drug screening in vitro and in vivo using transgenic luciferase expressing Plasmodium berghei parasites. International Journal for Parasitology, 2008, 38, 1651-1662.	1.3	69
24	Impairment of human CYP1A2-mediated xenobiotic metabolism by Antley–Bixler syndrome variants of cytochrome P450 oxidoreductase. Archives of Biochemistry and Biophysics, 2008, 475, 93-99.	1.4	49
25	Genotoxicity and endoreduplication inducing activity of the food flavouring eugenol. Mutagenesis, 2006, 21, 199-204.	1.0	60
26	The stimulatory role of human cytochrome b5 in the bioactivation activities of human CYP1A2, 2A6 and 2E1: a new cell expression system to study cytochrome P450 mediated biotransformation. Mutagenesis, 2005, 20, 93-100.	1.0	22
27	Escherichia coli BTC, a human cytochrome P450 competent tester strain with a high sensitivity towards alkylating agents: involvement of alkyltransferases in the repair of DNA damage induced by aromatic amines. Mutagenesis, 2005, 20, 199-208.	1.0	23
28	DNA Polymorphisms as Modulators of Genotoxicity and Cancer. Biological Chemistry, 2002, 383, 923-32.	1.2	9
29	Heterologous Expression of Xenobiotic Mammalian-Metabolizing Enzymes in Mutagenicity Tester Bacteria: An Update and Practical Considerations. Critical Reviews in Toxicology, 2000, 30, 287-306.	1.9	14
30	Escherichia coli MTC, a NADPH cytochrome P450 reductase competent mutagenicity tester strain for the expression of human cytochrome P450: Comparison of three types of expression systems. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 1999, 439, 287-300.	0.9	21
31	Escherichia coli MTC, a human NADPH P450 reductase competent mutagenicity tester strain for the expression of human cytochrome P450 isoforms 1A1, 1A2, 2A6, 3A4, or 3A5: catalytic activities and mutagenicity studies. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 1999, 441, 73-83.	0.9	31
32	Expression of human cytochrome P450 1A2 in Escherichia coli: a system for biotransformation and genotoxicity studies of chemical carcinogens. Mutagenesis, 1998, 13, 263-269.	1.0	44
33	Characterization of enzyme activities and cofactors involved in bioactivation and bioinactivation of chemical carcinogens in the tester strains Escherichia coli K12 MX100 and Salmonella typhimurium LT2 TA100. Mutagenesis, 1997, 12, 245-254.	1.0	24
34	MX100, a new Escherichia coli tester strain for use in genotoxicity studies. Mutagenesis, 1996, 11, 327-333.	1.0	18
35	Isolation and prevalidation of an Escherichia coli tester strain for the use in mechanistic and metabolic studies of genotoxins. Mutation Research - Environmental Mutagenesis and Related Subjects Including Methodology, 1994, 312, 99-109.	0.4	10
36	Selected abstracts of the 22nd annual meeting of the European environmental mutagen society, 31 August–4 September 1992, Berlin (Germany). Mutation Research - Environmental Mutagenesis and Related Subjects Including Methodology, 1993, 291, 223-297.	0.4	1

#	Article	IF	CITATIONS
37	Metabolic activation of mutagens by human haemoglobin. Mutation Research - Environmental Mutagenesis and Related Subjects Including Methodology, 1990, 234, 402.	0.4	1
38	Non-Specific Binding of the Fluorescent B-Adrenergic Receptor Probe Alprenolol-NBD. Journal of Receptors and Signal Transduction, 1985, 5, 121-131.	1.2	10
39	Role of Protein-Protein Interactions in Metabolism: Genetics, Structure, Function. Frontiers Research Topics, 0, , .	0.2	0